Skin immunization for effective treatment of multifocal melanoma refractory to PD1 blockade and Braf inhibitors
Background Despite the remarkable benefits associated with the interventional treatment of melanomas (and other solid cancers) with immune checkpoint and Braf inhibitors (Brafi), most patients ultimately progress on therapy. The presence of multifocal/disseminated disease in patients increases their...
Main Authors: | Xingxing Hao, Louis D Falo III, Jiying Zhang, Cara D Carey, Louis D Falo Jr, Zhaoyang You |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2021-01-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Online Access: | https://jitc.bmj.com/content/9/1/e001179.full |
Similar Items
-
Targeting Mitochondrial Oxidative Stress to Mitigate UV-Induced Skin Damage
by: Rhonda M. Brand, et al.
Published: (2018-08-01) -
Intratumoral delivery of tumor antigen-loaded DC and tumor-primed CD4+ T cells combined with agonist α-GITR mAb promotes durable CD8+ T-cell-dependent antitumor immunity
by: Zuqiang Liu, et al.
Published: (2017-06-01) -
Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations
by: Paolo A. Ascierto, et al.
Published: (2019-03-01) -
Skin Immunization Obviates Alcohol-Related Immune Dysfunction
by: Rhonda M. Brand, et al.
Published: (2015-11-01) -
Systems Analysis of Adaptive Responses to MAP Kinase Pathway Blockade in BRAF Mutant Melanoma.
by: Brian J Capaldo, et al.
Published: (2015-01-01)